Tom Powles on RCC patients receiving ICI therapy
Tom Powles shared on X:
“During the period of PD-1 inhibition availability for RCC in the UK only 60% of patients with progressive renal cancers (n>1000) received ICI therapy(1st-3rd line).
This occurred across IMDC risk groups.
Assuming all patients will eventually receive ICI is not supported by data.”
Source: Tom Powles/X
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre.
With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023